Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeOne Medicines
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Biopsy-confirmed PMN within 5 years before the initial screening (ie, the day the informed consent is signed)
UPCR (based on 24-hour urine collection) \> 3.5 at initial screening and at confirmation assessment
Treatment with a maximally tolerated or allowed dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for ≥ 24 weeks before randomization (12 weeks before initiation of study drug for Part 1) and with adequate blood pressure control (blood pressure \< 130/80 mmHg, measured on ≥ 2 occasions \[not on the same day\] within 4 weeks before the assignment of study treatment)
Participants with a secondary cause of membranous nephropathy
Type 1 or 2 diabetes mellitus with hemoglobin A1c (HbA1c) ≥ 7% at screening
Severe renal disease as determined by rapid decline in eGFR (defined as \> 15 mL/min/1.73m\^2 within 24 weeks prior to randomization, not otherwise explained)
A known history of a primary immunodeficiency or an underlying condition such as human immunodeficiency virus (HIV) infection or splenectomy that predisposes the participant to infections
Patients at risk for tuberculosis at screening
Known infection with serologic status reflecting active or chronic hepatitis B virus infection, or presence of hepatitis C virus antibody
